Regulation - UCB

Filter

Current filters:

UCB

Popular Filters

Actavis confirms patent challenge for generic Neupro

Actavis confirms patent challenge for generic Neupro

23-08-2014

Ireland-headquartered generics major Actavis on Friday confirmed that it has filed an Abbreviated New…

ActavisGenericsLegalNeuproNeurologicalPatentsRegulationUCBUSA

UCB’s Cimzia granted additional indication by US FDA

UCB’s Cimzia granted additional indication by US FDA

30-09-2013

UCB revealed today that the US Food and Drug Administration has approved its currently marketed drug…

Anti-Arthritics/RheumaticsCimziaNorth AmericaPharmaceuticalRegulationUCB

Actavis confirms Vimpat patent challenge and gets OK for generic Opana

15-07-2013

US generics major Actavis (NYSE: ACT) confirmed on Friday (July 12) that it has filed an Abbreviated…

ActavisEndo Health SolutionsGenericsLegalNeurologicalNorth AmericaOpana ERPatentsRegulationUCBVimpat

UCB files for US and EU approval for Cimzia for psoriatic arthritis and axial spondyloarthritis

20-02-2013

Belgium's largest drugmaker, UCB (Euronext Brussels: UCB) says it has made two new regulatory filings…

Anti-Arthritics/RheumaticsCimziaEuropeNorth AmericaPharmaceuticalRegulationUCB

FDA approves UCB drug Neupro for PD and RLS

03-04-2012

Belgian drugmaker UCB (Euronext Brussels: UCB) said yesterday that the US Food and Drug Administration…

NeuproNeurologicalNorth AmericaPharmaceuticalRegulationUCB

Back to top